• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » MIT Report: IBM Watson, machine-learning plays “overhyped”

MIT Report: IBM Watson, machine-learning plays “overhyped”

June 28, 2017 By Fink Densford

IBM's Watson Health

IBM (NYSE:IBM) Watson Health, and other machine-learning company’s immediate impact on healthcare may have been significantly overhyped, promoting a timeline  that it may not be able to reach, according to a new article from MIT’s Technology Review.

The fault lies not with the company, however, but the complexity and relative unavailability of data that it and others machine-learning systems needs to “learn,” according to the article.

Machine learning processes require constant adjustments to internal processing routines to produce the highest possible percentage of correct answers to a set of problems, according to the article. This process works well with cases where it’s easy to identify problems or solutions, such as malignancies in X-rays, but becomes exponentially harder with cases in which the relationship is unknown.

“But for potentially groundbreaking puzzles that go well beyond what humans already do, like detecting the relationships between gene variations and disease, Watson has a chicken-and-egg problem: how does it train on data that no experts have already sifted through and properly organized?” article author David Freedman wrote.

When teaching a self-driving car and it’s machine-learning systems, anyone can label trees or signs to be recognized, but with medical data, it takes specialized training and deep knowledge to make such decisions, the article argues.

Another issue with machine-learning, AI-driven solutions in healthcare is a lack of data on patients outside health records, including eating habits, drug use, air quality and other factors, the author argues. Part of the reason that data is hard to find is because hospitals have been slow to take up modern data-driven practices, according to the article.

IBM Watson Health actually has a significant leg up on the competition, according to the author, as it has the ability to acquire data that other machine-learning plays can’t. The company has acquired Truven Health Analytics, Exployrs and Phytel, all of whom are dealing with large data sets. The company also has partnerships with other companies which provide it with more data, and therefore the ability to train its system more efficiently.

While machine-learning has been overhyped, the author argues, there’s still a chance that Watson and other companies like it will make a significant difference in health outcomes, just not as quickly as they had promised.

Filed Under: Business/Financial News, Software / IT Tagged With: IBM Watson Health

More recent news

  • Mount Sinai adopts Flosonics wearable ultrasound device
  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy